KLOW Peptide Blend benefits and uses

Evidence at a glance

KLOW has never been studied as a blend, so what sources report comes from research on its four peptides, one or two at a time.¹ The table gives each peptide's strongest reported finding and the kind of study behind it. None of these results came from a KLOW vial.

BPC-157: animal healing data, uncontrolled human reports

In rats with a cut Achilles tendon, daily BPC-157 improved load to failure, stiffness and Achilles function scores, while saline-treated rats healed poorly (2003).⁶ A 2025 systematic review found 36 eligible studies, 35 of them preclinical.⁷ In those animal models, BPC-157 improved functional, structural and biomechanical outcomes after muscle, tendon, ligament and bone injuries.⁷

Most of the human data are small and uncontrolled. In a retrospective chart review, 14 of 16 patients reported knee-pain relief after BPC-157 was injected into the knee, alone or with thymosin beta-4 (reported as TB4).⁸ A 2026 review said significant methodological flaws and a lack of controls limit that report.⁹ In a pilot study without a control group, 10 of 12 women with interstitial cystitis reported complete symptom resolution after one BPC-157 treatment.¹⁰ A randomized trial in 53 adults with ulcerative colitis is known only from a 2005 meeting abstract, and FDA concluded the evidence does not support effectiveness.¹¹ Profile: What is BPC-157?

TB-500: one rat study, plus data on a different molecule

TB-500 is an acetylated copy of amino acids 17 to 23 of human thymosin beta-4.¹⁴ Evidence for TB-500 itself is thin. FDA's 2026 review found no information on TB-500 given to patients.¹³ In a 2024 lab study, it did not speed wound closure in cultured fibroblasts, and the authors suggest that wound-healing activity reported earlier may come from its breakdown product, Ac-LKKTE.¹² Its main positive result is the 2026 rat study described above.⁵

Most other positive results belong to full-length thymosin beta-4, not TB-500. In rats, thymosin beta-4 increased re-epithelialization (regrowth of the skin's surface layer) of full-thickness wounds by 42% at day 4 and by up to 61% at day 7, compared with saline.¹⁵ In people, thymosin beta-4 eye drops met key efficacy objectives in a 9-person phase 2 trial for severe dry eye,¹⁶ and a review reports that in two phase 2 trials of stasis and pressure ulcers it sped healing by almost a month in the patients whose ulcers healed.¹⁷ Full list: TB-500 benefits and uses

KPV: animal studies of gut inflammation

KPV is alpha-MSH(11-13), a three-amino-acid piece of the hormone alpha-MSH.¹⁹ Given by mouth, it reduced the incidence of chemically induced (DSS and TNBS) colitis in mice in a 2008 study.¹⁸ A second 2008 team found significant anti-inflammatory effects in two mouse colitis models, effects at least partly independent of the MC1R melanocortin receptor.¹⁹ FDA found no data, such as clinical studies, on KPV use in humans.²⁰ Full list: KPV benefits and uses

GHK-Cu: gel and cosmetic data

In a multicenter, randomized, evaluator-blinded, placebo-controlled trial (1994), people with diabetic neuropathic ulcers were treated daily with a GHK-copper gel.²¹ Median area closure of plantar ulcers was 98.5%, against 60.8% with the plain gel.²¹ In ulcers treated right after debridement, infections were less common with the active gel: 7% against 34%.²² A 2015 review reports that GHK in cosmetic products tightened loose skin, improved elasticity, density and firmness and reduced fine lines and wrinkles, and that GHK induced systemic wound healing in rats, mice and pigs.²³ A 2026 review found no clinical data supporting GHK-Cu for musculoskeletal conditions.²⁴ Profile: What is GHK-Cu?

Does combining them add anything?

No study has tested whether the four peptides act together, in any species.¹ A 2026 rat study tested two of the four together, BPC-157 and TB-500.⁴ In 32 rats after Achilles tendon repair, giving both for 4 weeks brought no added benefit over either peptide alone.⁴⁵

Two more gaps separate these findings from a KLOW vial. The amount of each peptide in the blend is not disclosed, so it cannot be matched to the amounts used in studies, which are listed in KLOW Peptide Blend dosage. And the human results above for GHK-Cu and thymosin beta-4 include a gel on ulcers and eye drops, not a freeze-dried mix of four peptides.²¹¹⁶

Uses people search for

KLOW is searched alongside several goals. What the sources above support for each:

• Healing and recovery. The case rests on animal studies.⁷ A 2026 scoping review found few human studies of these peptides, most without robust controls, and called their claimed musculoskeletal benefits unsubstantiated by human trials.²⁵ More: Peptides and healing and recovery.
• Skin and hair. The human evidence is for GHK-Cu used on the skin, such as a 2026 double-blind split-face eyebrow study in 18 healthy participants that reported higher hair count and diameter with a 2% GHK-Cu serum; a 13-participant study after laser treatment found no objective advantage.²⁶ FDA says there are limited human data to inform the safety of injected GHK-Cu.²⁷ More: Peptides and skin and hair.
• Muscle. BPC-157 improved healing of injured muscle in animal models,⁷ and GHK-Cu treatment reduced muscle loss and weakness caused by cigarette smoke in mice.²⁸ No human trial has shown that these peptides build muscle, and the 2026 scoping review calls claimed performance benefits unsubstantiated.²⁵ More: Peptides and muscle growth.
• Weight loss and sleep. No study of KLOW has measured either.¹ Among its parts, a 2026 study found that KPV given by mouth reduced body weight gain and fat tissue growth in mice fed a high-fat diet.²⁹ More: Peptides and weight loss and Peptides and sleep.

Related pages

The full profile is What is KLOW Peptide Blend?, and reported harms are in KLOW Peptide Blend side effects. How mixed vials differ from single peptides is covered in Peptide blends and stacks. The vial is listed as KLOW Peptide Blend for sale under the store's research use policy.